Nuvectis Pharma Q3 2024 net loss $4.2M; NXP800 data update expected November

Nuvectis Pharma, Inc.

2024-Q3 EPS reported -$0.75

Net loss $4.2M in Q3 2024 vs $5.9M Q3 2023; R&D expenses $2.8M vs $4.5M.
Cash, cash equivalents and short-term investments $17.2M as of Sep 30, 2024 (vs $19.1M Dec 31, 2023); runway into 2026.
NXP800 Phase 1b clinical data update expected November 2024; received FDA Orphan Drug Designation for ARID1a-deficient ovarian cancers.
NXP900 Phase 1a dose escalation: 4 cohorts completed with no DLTs; dose continuing; combo plans in NSCLC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.